Events Archives - Page 36 of 128

2 minute read

SELLAS Life Sciences To Present Final Data From Phase 1/2 Study Of Galinpepimut-S In Combination With Keytruda In Patients With WT1+ Platinum-Resistant Advanced Ovarian Cancer At The International Gynecologic Cancer Society 2023 Annual Global Meeting

October 17, 8:45 AM

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today

SLS

2 minute read

MAIA Biotechnology To Present Latest Findings For Second Generation THIO Program At Turkish Biochemical Society’s International Biochemistry Congress 2023

By Happy Mohamed

October 17, 8:23 AM

MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced its participation in the International Biochemistry Congress 2023, organized by the

MAIA

3 minute read

Cellectar Biosciences Expands Commercialization Leadership Team Ahead Of Pivotal Data for Iopofosine I-131 in Waldenstrom’s Macroglobulinemia

By Happy Mohamed

October 17, 8:21 AM

William Yoon Appointed Vice President, Medical Affairs Aaditya Nanduri Appointed Vice President, Business Strategy and Analytics FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.

CLRB

2 minute read

NKGen Biotech Presents Interim Phase I Trial Data At The XXVI World Congress Of Neurology Annual Meeting 2023

By Happy Mohamed

October 17, 8:20 AM

NKGen Biotech Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK

NKGN

1 minute read

Sutro Demonstrates Meaningful ADC Innovation With Five Presentations And One Poster At The 14th Annual World ADC Conference

By Benzinga Newsdesk

October 16, 4:06 PM

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five

STRO

3 minute read

Natera To Present New Signatera MRD Data At ESMO 2023, Featuring Large, Updated Analysis From CIRCULATE-Japan Study

By Benzinga Newsdesk

October 16, 9:08 AM

Presentations include largest analysis from the GALAXY study in colorectal cancer with updated 24-month disease-free survival data, and expanded Signatera readout in rectal cancerNatera, Inc. (NASDAQ:NTRA), a global

NTRA

3 minute read

Aprea Unveils Initial Clinical Data On ATRi, ATRN-119, And Pre-Clinical Data On WEE1i, ATRN-1051, At AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

By Benzinga Newsdesk

October 16, 8:45 AM

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced highlights of two posters

APRE

4 minute read

Theriva Biologics Announces Presentation At ESMO Congress 2023 Featuring Survival Outcomes In Phase 1 Study Evaluating VCN-01 In Combination With Durvalumab In Patients With Recurrent/Metastatic Squamous Cell Carcinoma Of The Head And Neck

By Benzinga Newsdesk

October 16, 8:31 AM

-Results from investigator-sponsored study in collaboration with the Institut Catala d'Oncologia (ICO) show enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1- -Key Opinion Leader

TOVX

1 minute read

SCYNEXIS To Present Preclinical Data On Second Generation Fungerp SCY-247 At The 11th Congress On Trends In Medical Mycology October 20-23 In Athens, Greece

By Benzinga Newsdesk

October 16, 8:27 AM

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its

SCYX

3 minute read

Entera Bio Reports Rapid Pharmacodynamic Response And Consistent Pharmacokinetic Data For Its First-In-Class Oral PTH(1-34) Mini Tablets At The ASBMR 2023 Annual Meeting

By Benzinga Newsdesk

October 16, 8:20 AM

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, presented 2 posters at the Annual Society of Bone and Mineral Research (ASBMR)

ENTX